Patents by Inventor Patrick J. Killela

Patrick J. Killela has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11306364
    Abstract: We surveyed 1,230 tumors of 60 different types and found that tumors could be divided into types with low (<15%) and high (?15%) frequencies of TERT promoter mutations. The nine TERT-high tumor types almost always originated in tissues with relatively low rates of self renewal, including melanomas, liposarcomas, hepatocellular carcinomas, urothelial carcinomas, squamous cell carcinomas of the tongue, medulloblastomas, and subtypes of gliomas (including 83% of primary glioblastoma, the most common brain tumor type). TERT and ATRX mutations were mutually exclusive, suggesting that these two genetic mechanisms confer equivalent selective growth advantages. In addition to their implications for understanding the relationship between telomeres and tumorigenesis, TERT mutations provide a biomarker for the early detection of urinary tract and liver tumors and aid in the classification and prognostication of brain tumors.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: April 19, 2022
    Assignees: Duke University, The Johns Hopkins University
    Inventors: Hai Yan, Bert Vogelstein, Nickolas Papadopoulos, Kenneth W. Kinzler, Yuchen Jiao, Chetan Bettegowda, Darell D. Bigner, Zachary J. Reitman, Patrick J. Killela
  • Publication number: 20200399708
    Abstract: We surveyed 1,230 tumors of 60 different types and found that tumors could be divided into types with low (<15%) and high (?15%) frequencies of TERT promoter mutations. The nine TERT-high tumor types almost always originated in tissues with relatively low rates of self renewal, including melanomas, liposarcomas, hepatocellular carcinomas, urothelial carcinomas, squamous cell carcinomas of the tongue, medulloblastomas, and subtypes of gliomas (including 83% of primary glioblastoma, the most common brain tumor type). TERT and ATRX mutations were mutually exclusive, suggesting that these two genetic mechanisms confer equivalent selective growth advantages. In addition to their implications for understanding the relationship between telomeres and tumorigenesis, TERT mutations provide a biomarker for the early detection of urinary tract and liver tumors and aid in the classification and prognostication of brain tumors.
    Type: Application
    Filed: July 14, 2020
    Publication date: December 24, 2020
    Applicants: Duke University, The Johns Hopkins University
    Inventors: Hai Yan, Bert Vogelstein, Nickolas Papadopoulos, Kenneth W. Kinzler, Yuchen Jiao, Chetan Bettegowda, Darell D. Bigner, Zachary J. Reitman, Patrick J. Killela
  • Patent number: 10711310
    Abstract: We surveyed 1,230 tumors of 60 different types and found that tumors could be divided into types with low (<15%) and high (?15%) frequencies of TERT promoter mutations. The nine TERT-high tumor types almost always originated in tissues with relatively low rates of self renewal, including melanomas, liposarcomas, hepatocellular carcinomas, urothelial carcinomas, squamous cell carcinomas of the tongue, medulloblastomas, and subtypes of gliomas (including 83% of primary glioblastoma, the most common brain tumor type). TERT and ATRX mutations were mutually exclusive, suggesting that these two genetic mechanisms confer equivalent selective growth advantages. In addition to their implications for understanding the relationship between telomeres and tumorigenesis, TERT mutations provide a biomarker for the early detection of urinary tract and liver tumors and aid in the classification and prognostication of brain tumors.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: July 14, 2020
    Assignees: Duke University, The Johns Hopkins University
    Inventors: Hai Yan, Bert Vogelstein, Nickolas Papadopoulos, Kenneth W. Kinzler, Yuchen Jiao, Chetan Bettegowda, Darell D. Bigner, Zachary J. Reitman, Patrick J. Killela